{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:08:21Z","timestamp":1790665701963,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.critrevonc.2008.10.013","type":"journal-article","created":{"date-parts":[[2008,12,14]],"date-time":"2008-12-14T09:45:40Z","timestamp":1229247940000},"page":"10-20","source":"Crossref","is-referenced-by-count":59,"title":["Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice"],"prefix":"10.1016","volume":"72","author":[{"given":"Nicolas","family":"Mounier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose-Marie","family":"Chichmanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2008.10.013_bib1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/oxfordjournals.aje.a117008","article-title":"Risk of other cancers following Kaposi's sarcoma: relation to acquired immunodeficiency syndrome","volume":"139","author":"Biggar","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib2","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(97)09028-4","article-title":"Spectrum of AIDS-associated malignant disorders","volume":"351","author":"Goedert","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib3","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/01.aids.0000238411.75324.59","article-title":"Trends in cancer risk among people with AIDS in the United States 1980\u20132002","volume":"20","author":"Engels","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/cncr.20354","article-title":"Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy","volume":"101","author":"Bonnet","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jnci\/dji072","article-title":"Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy","volume":"97","author":"Clifford","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib6","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2003.01.096","article-title":"Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients","volume":"21","author":"Herida","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2008.10.013_bib7","first-page":"462","article-title":"Cancer risk and mortality for patients with HIV in the combination antiretroviral therapy era: evolving epidemiology","author":"Costagliola","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.cco.0000239886.13537.ed","article-title":"The growing problem of non-AIDS-defining malignancies in HIV","volume":"18","author":"Pantanowitz","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib9","series-title":"Conference on retroviruses and opportunistic infections","article-title":"Immunodeficiency and risk of AIDS-defining and non-AIDS-defining cancers: ANRS CO3 Aquitaine Cohort, 1998 to 2006","author":"Bruyand","year":"2008"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.qai.0000164033.02947.e3","article-title":"Survival after cancer diagnosis in persons with AIDS","volume":"39","author":"Biggar","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1470-2045(07)70036-0","article-title":"Management of AIDS-related Kaposi's sarcoma","volume":"8","author":"Di Lorenzo","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2141.2006.06464.x","article-title":"Modern management of non-Hodgkin lymphoma in HIV-infected patients","volume":"136","author":"Mounier","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00003088-199936040-00004","article-title":"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection","volume":"36","author":"Barry","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1023\/A:1013164013375","article-title":"Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents","volume":"12","author":"Sekine","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib15","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1998.16.2.683","article-title":"Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group","volume":"16","author":"Stewart","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib17","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","article-title":"Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma","volume":"14","author":"Gill","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib18","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.1999.17.6.1876","article-title":"Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma","volume":"17","author":"Gill","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.1998.16.3.1112","article-title":"Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma","volume":"16","author":"Welles","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B","article-title":"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related non-Hodgkin lymphoma","volume":"91","author":"Vaccher","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib21","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with doseadjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology","volume":"101","author":"Little","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib22","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma","volume":"24","author":"Boue","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib23","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib24","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdg408","article-title":"BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection","volume":"14","author":"Hartmann","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib25","unstructured":"DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel's \u2013 US Guideline 2008. New York State Department of Health AIDS Institute. Clinical Guidelines. HIV Drug\u2013Drug Interactions. Available at: http:\/\/www.hivguidelines.org. Accessed July 10, 2003."},{"key":"10.1016\/j.critrevonc.2008.10.013_bib26","first-page":"433","article-title":"Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs","volume":"13","author":"Faragon","year":"2003","journal-title":"AIDS Read"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","article-title":"Drug interactions in cancer therapy","volume":"6","author":"Scripture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200544020-00001","article-title":"Interactions between antiretrovirals and antineoplastic drug therapy","volume":"44","author":"Antoniou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib29","first-page":"386","article-title":"Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation","volume":"54","author":"Cresteil","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib30","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1200\/JCO.1998.16.5.1811","article-title":"Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264","volume":"16","author":"Venook","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib31","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1200\/JCO.1991.9.7.1261","article-title":"A phase I trial of taxol given by a 6-hour intravenous infusion","volume":"9","author":"Brown","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib32","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1200\/JCO.1996.14.6.1877","article-title":"Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer","volume":"14","author":"Seidman","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib33","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s002800050932","article-title":"Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma-drug\u2013drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study","volume":"43","author":"Panday","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib34","first-page":"A829","article-title":"Pharmacokinetics of low-dose paxene (paclitaxel) in patients with refractory or relapsed AIDS-related Kaposi's sarcoma","author":"Duchin","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002030-199902040-00019","article-title":"Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma","volume":"13","author":"Schwartz","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.coc.0000045921.91037.C8","article-title":"Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma","volume":"27","author":"Bundow","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib37","first-page":"A2194","article-title":"Interaction between highly active antiretroviral therapy (HAART) and taxanes: a report of two cases","volume":"21","author":"Parameswaran","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clpt.2006.02.003","article-title":"Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms","volume":"79","author":"Tran","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/JCO.1996.14.1.58","article-title":"Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer","volume":"14","author":"Hudis","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2000.18.3.562","article-title":"Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients","volume":"18","author":"Alexandre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/annonc\/mdl321","article-title":"Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study","volume":"18","author":"Alexandre","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib42","first-page":"6158","article-title":"Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir","volume":"62","author":"Bardelmeijer","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib43","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0006-2952(99)00410-4","article-title":"Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide","volume":"59","author":"Huang","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2125.2000.00269.x","article-title":"Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study","volume":"50","author":"Freyer","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib45","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2001.19.8.2171","article-title":"Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy","volume":"19","author":"Ratner","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib46","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1200\/JCO.2005.05.128","article-title":"Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide","volume":"23","author":"Bower","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib47","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2004-05-1747","article-title":"Protease inhibitors potentiate chemotherapy-induced neutropenia","volume":"104","author":"Bower","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-3565(24)39081-0","article-title":"Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance","volume":"294","author":"Yao","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib49","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0609.2007.00827.x","article-title":"Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease","volume":"78","author":"Makinson","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib50","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2435.x","article-title":"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease","volume":"76","author":"Kotb","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tiv.2005.06.045","article-title":"Pharmacogenetics of irinotecan metabolism and transport: an update","volume":"20","author":"Smith","year":"2006","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib52","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.clpt.6100330","article-title":"Lopinavir\u2013ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma","volume":"83","author":"Corona","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib54","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib55","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000180790.77379.3a","article-title":"Potential hazard of pharmacokinetic interactions between lopinavir\u2013ritonavir protease inhibitors and irinotecan","volume":"19","author":"Corona","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib56","first-page":"641","article-title":"Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins","volume":"8","author":"Garcia-Carbonero","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/BF02787345","article-title":"Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma","volume":"15","author":"Sparano","year":"1998","journal-title":"Med Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib58","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2004.08.195","article-title":"Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494)","volume":"22","author":"Sparano","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib59","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0026-895X(25)13375-0","article-title":"Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes","volume":"44","author":"Goeptar","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib60","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/annonc\/mdh464","article-title":"Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma","volume":"15","author":"Toffoli","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib61","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s002800051025","article-title":"The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma","volume":"45","author":"Fumagalli","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib62","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/ajhp\/60.12.1233","article-title":"Targeted drugs in oncology: new names, new mechanisms, new paradigm","volume":"60","author":"Rotea","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib63","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/jnci\/djj466","article-title":"CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors","volume":"98","author":"Li","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib64","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","article-title":"Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2515\/therapie:2007021","article-title":"Pharmacokinetic\u2013pharmacodynamics relationships of imatinib (Glivec)","volume":"62","author":"Delbaldo","year":"2007","journal-title":"Therapie"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib67","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/mol.56.2.383","article-title":"Interactions of HIV protease inhibitors with ATP-dependent drug export proteins","volume":"56","author":"Gutmann","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-4615-1173-1_3","article-title":"MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents","volume":"112","author":"Deng","year":"2002","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00042560-200208010-00001","article-title":"In vitro and in vivo modulation of MDR1\/p-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin","volume":"30","author":"Lucia","year":"2002","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib70","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-108-3-372","article-title":"Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome and Kaposi sarcoma with zidovudine","volume":"108","author":"Walker","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib71","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00002018-199819060-00005","article-title":"Peripheral neuropathy with nucleoside antiretroviral: risk factors, incidence and management","volume":"19","author":"Moyle","year":"1998","journal-title":"Drug Safe"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib72","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib73","first-page":"1139","article-title":"Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor","volume":"93","author":"Mounier","year":"2006","journal-title":"Bull Cancer"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib74","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib75","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-Moller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib76","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0953-6205(02)00029-8","article-title":"AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Part I. Kaposi's sarcoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma","volume":"13","author":"Spano","year":"2002","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.critrevonc.2008.10.013_bib77","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0953-6205(02)00063-8","article-title":"AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Part II. Cervical and anal squamous epithelial lesions, lung cancer, testicular germ cell cancers, and skin cancers","volume":"13","author":"Spano","year":"2002","journal-title":"Eur J Intern Med"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084280800276X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084280800276X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:14:50Z","timestamp":1738818890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084280800276X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S104084280800276X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2008.10.013","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}